Pancreatic cancer orthotopic

products-servicesPharmatest Services Ltd
June 11th 2014

The prognosis for pancreatic cancer remains poor, with less than one in 20 patients still living five years post-diagnosis and complete remission being extremely rare. There are also very few treatment options available. Therefore pancreatic cancer is considered an unmet clinical need.

Pharmatest offers an orthotopic pancreatic cancer model that is suitable for testing the efficacy of drug compounds against primary tumor growth and responds to clinically relevant treatment (gemcitabine).

Description

The Pharmatest orthotopic pancreatic cancer model involves a surgical procedure in which human pancreatic adenocarcinoma cells are inoculated into the pancreas of an immunodeficient mouse.

The major advantage of using orthotopic models is to maintain the proper tissue microenvironment that is known to affect tumor growth, metastasis and drug resistance.

At the end of the experiment, inoculated animals are euthanized, with primary tumor and selected organs collected for further analysis. From histological sections several additional parameters can be studied immunohistochemically, including angiogenesis, hypoxia, proliferation rate and apoptosis.

Resources

Click on pancreatic cancer orthotopic model for other information.
Click on Pharmatest to contact the company directly.


Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com